Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $236.47, for a total value of $851,292.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,741.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Up 0.2 %

Shares of NASDAQ:UTHR opened at $234.47 on Wednesday. The firm has a market cap of $11.03 billion, a price-to-earnings ratio of 11.82 and a beta of 0.52. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The stock’s 50-day moving average price is $232.48 and its two-hundred day moving average price is $228.69.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.67 EPS. On average, research analysts forecast that United Therapeutics Co. will post 23.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on UTHR shares. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and raised their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Wedbush restated an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, HC Wainwright restated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System lifted its stake in shares of United Therapeutics by 2.3% in the 1st quarter. Louisiana State Employees Retirement System now owns 13,500 shares of the biotechnology company’s stock valued at $3,101,000 after purchasing an additional 300 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in shares of United Therapeutics by 38.2% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 1,439 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 398 shares in the last quarter. IFM Investors Pty Ltd acquired a new position in shares of United Therapeutics in the 1st quarter valued at about $2,238,000. First Trust Direct Indexing L.P. lifted its stake in shares of United Therapeutics by 38.0% in the 1st quarter. First Trust Direct Indexing L.P. now owns 2,107 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 580 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in shares of United Therapeutics by 153.5% in the 1st quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company’s stock valued at $3,802,000 after purchasing an additional 10,025 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.